Capital World Investors Acquires 3,331,542 Shares of Illumina, Inc. $ILMN

Key Points

• Capital World Investors raised its Illumina stake by 20% in Q3, buying an additional 3,331,542 shares to hold 19,976,850 shares (13.07% of the company) valued at about $1.897 billion.
• Several other large funds also materially increased positions (AQR +55.3%, Edmond de Rothschild +140.1%, Thrivent +1,558%, Invesco +48.9%), leaving institutional investors with roughly 89.42% ownership of Illumina stock.
• Illumina beat quarterly estimates with $1.35 EPS vs. $1.26 expected and $1.16B revenue vs. $1.10B, set FY2026 EPS guidance of 5.050–5.200, and carries an average analyst rating of "Hold" with a $129.69 target.

Capital World Investors increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 20.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 19,976,850 shares of the life sciences company's stock after acquiring an additional 3,331,542 shares during the period. Capital World Investors owned 13.07% of Illumina worth $1,897,178,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. AQR Capital Management LLC increased its position in Illumina by 55.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company's stock worth $313,290,000 after buying an additional 1,174,295 shares during the period. Edmond DE Rothschild Holding S.A. grew its position in Illumina by 140.1% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company's stock valued at $136,312,000 after acquiring an additional 833,750 shares during the period. Thrivent Financial for Lutherans increased its position in shares of Illumina by 1,558.0% during the 2nd quarter. Thrivent Financial for Lutherans now owns 728,755 shares of the life sciences company's stock worth $69,528,000 after purchasing an additional 684,802 shares in the last quarter. Pacer Advisors Inc. acquired a new position in Illumina in the third quarter worth $61,663,000. Finally, Invesco Ltd. increased its position in Illumina by 48.9% in the 2nd quarter. Invesco Ltd. now owns 1,353,077 shares of the life sciences company's stock valued at $129,097,000 after acquiring an additional 444,543 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. TD Cowen restated a "hold" rating on shares of Illumina in a research report on Wednesday, January 7th. Barclays raised their price target on Illumina from $100.00 to $110.00 and gave the stock an "underweight" rating in a research report on Monday, December 15th. Wall Street Zen raised shares of Illumina from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 14th. JPMorgan Chase & Co. reduced their target price on shares of Illumina from $130.00 to $120.00 and set a "neutral" rating for the company in a report on Friday, February 6th. Finally, Robert W. Baird set a $137.00 price target on Illumina in a research note on Friday, February 6th. Six investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $129.69.

Illumina Trading Down 0.3%

ILMN opened at $124.28 on Tuesday. The company's 50 day moving average is $134.17 and its 200-day moving average is $119.55. The company has a market cap of $19.00 billion, a P/E ratio of 22.80, a PEG ratio of 2.38 and a beta of 1.45. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $155.53.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the prior year, the firm posted $0.95 earnings per share. The firm's revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In related news, insider Scott M. Davies sold 323 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the sale, the insider directly owned 17,887 shares of the company's stock, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Patricia Leckman sold 2,370 shares of the firm's stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.17% of the company's stock.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.